U.S. Marine and Shipping Stock News

If you are wondering whether Revvity is priced attractively right now, this article walks through what the current share price might be implying about value. The stock recently closed at US$110.14, with returns of 4.8% over 7 days, 9.6% over 30 days and 12.2% year to date. The 1 year, 3 year and 5 year returns stand at an 8.5% decline, 16.2% decline and 25.4% decline respectively. Recent coverage has focused on Revvity's position in pharmaceuticals and biotech and how investors are assessing...

Romanian startup .lumen has announced a collaboration with Arrow Electronics to scale production of its AI-powered intelligent guide glasses, which use six cameras and real-time haptic feedback to support safe navigation for visually impaired users and were recognized as a CES 2026 Innovation Awards Honoree in Accessibility and Longevity. The partnership showcases Arrow’s role in engineering and supply chain support for advanced assistive wearables, underlining its expanding reach into...

In January 2026, Energy Transfer LP completed three tranches of fixed-rate, callable senior unsecured notes totaling about US$3.00 billion, with coupons of 4.550% (due 2031), 5.350% (due 2036), and 6.300% (due 2056), primarily to refinance existing debt and fund general partnership purposes. This large, long-dated bond issuance underscores Energy Transfer’s focus on locking in funding for its growth projects while supporting its fee-based cash flow and planned distribution growth. We’ll now...

Viking Holdings (VIK) is drawing fresh attention after announcing a multi year marketing partnership with the PGA TOUR, which designates the company as the Official Cruise Line through 2030 across TOUR platforms. See our latest analysis for Viking Holdings. Despite the PGA TOUR partnership drawing new attention, Viking Holdings’ recent 7 day share price return of a 3.42% decline contrasts with a stronger 90 day share price return of 15.87%, while the 1 year total shareholder return of 64.82%...

If you are wondering whether Becton Dickinson is offering fair value at its current share price, you are not alone; many investors are asking the same question. The stock recently closed at US$201.52, with a 7 day return of a 1.9% decline, a 30 day return of 0.3%, and a year to date return of 3.4%, while the 1 year return stands at a 12.7% decline and the 3 and 5 year returns are 17.0% and 14.1% declines respectively. Recent attention on Becton Dickinson has been driven by ongoing interest...

If you are wondering whether Elastic's share price lines up with what the business is actually worth today, or if the market is mispricing it, this article is for you. Elastic's stock last closed at US$75.34, with returns of 3.8% year to date, a 23.1% decline over the past year, and a 55.6% decline over five years, while the three-year return stands at 43.5%. Recent coverage around Elastic has focused on its position in search and data analytics software and how investors are reassessing...

Reddit (RDDT) is drawing attention after recent trading, with the stock last closing at $258.93. Considering recent returns across the week, month, and past 3 months, many investors are reassessing expectations. See our latest analysis for Reddit. The recent 6.11% 1-day share price return and 15.19% 30-day share price return, alongside a 57.10% 1-year total shareholder return, point to momentum that has been building rather than fading as investors reassess Reddit’s risk and growth...

Boeing (BA) is back in focus after recent trading activity, with the share price closing at $244.55 and short term performance data providing investors with additional context on how the stock has moved over the past year. See our latest analysis for Boeing. Recent trading has been strong, with a 1-month share price return of 19.65% and a 1-year total shareholder return of 46.42%. This suggests momentum has been building as investors reassess Boeing’s prospects and risk profile. If Boeing’s...

Wondering if Home Depot at around US$379.74 is offering good value today, or if the price already reflects what you might expect from the business. The share price has recently moved, with returns of 8.7% over the last 7 days, 5.6% over 30 days, 9.8% year to date, 25.1% over 3 years, and 57.0% over 5 years, while the 1 year return sits at a 0.9% decline. Recent coverage has focused on Home Depot as a major US home improvement retailer, with investors watching how consumer spending on housing...

CRISPR Therapeutics (CRSP) recently outlined a packed 2026 roadmap, highlighting global CASGEVY commercialization, fresh regulatory submissions, and multiple readouts and trial starts across its in vivo and CAR T gene editing programs. See our latest analysis for CRISPR Therapeutics. The recent roadmap update and upcoming J.P. Morgan Healthcare Conference appearance come after a mixed year for the stock. The 1-year total shareholder return of 46.45% contrasts with a 21.78% decline in the 3...

If you are wondering whether DexCom's current share price lines up with its underlying worth, this article will walk through what the numbers are really saying about the stock. DexCom recently closed at US$70.25, with returns of 0.5% over 7 days, 4.9% over 30 days and 5.6% year to date, while the 1 year and 3 year returns sit at an 11.3% and 35.9% decline and the 5 year return at a 21.4% decline. Recent coverage around DexCom has focused on its position in glucose monitoring and how...

Beam Therapeutics (BEAM) has attracted investor attention after recent share price moves, with the stock closing at US$34.55 and showing double digit returns over the past month and over the past three months. See our latest analysis for Beam Therapeutics. Looking beyond the recent surge, Beam Therapeutics’ 1 month share price return of 26.28% and year to date share price return of 27.30% sit alongside a 1 year total shareholder return of 48.28%. This suggests momentum has recently been...

General Mills (GIS) is back in focus after second quarter results came in ahead of expectations on sales and profit, even as the company faces falling unit volumes and higher capital needs. See our latest analysis for General Mills. At a share price of $44.27, General Mills has seen a 1-day share price return of 1.82% but a 1-year total shareholder return decline of 20.92%. This suggests that recent momentum is still weak despite the earnings beat and comments about “improved momentum” in a...

Earlier this week, Labcorp expanded its molecular residual disease (MRD) portfolio, adding Plasma Detect ID for stage I–III breast and stage I–IIIA non-small cell lung cancer and making Plasma Detect Genome MRD testing for stage III colon cancer available nationwide, enabling highly sensitive detection of circulating tumor DNA after treatment. This push deeper into MRD testing reinforces Labcorp’s role in precision oncology, with ultra–low limit-of-detection ctDNA assays that aim to inform...

Enphase Energy has already begun U.S. production shipments of its IQ9N-3P Commercial Microinverter, a gallium nitride–based, three-phase 480Y/277 V device built domestically to meet content and FEOC compliance requirements for commercial solar projects. The launch extends Enphase’s panel-level microinverter architecture into the 480 V commercial market, aiming to simplify system design, trim installation costs, and enhance per-panel monitoring and safety for complex rooftop...

Bloom Energy (BE) is back in the spotlight after a fresh $2.65b expansion of its American Electric Power partnership for solid oxide fuel cells tied to AI hungry data centers. See our latest analysis for Bloom Energy. The latest American Electric Power deal comes after several AI focused data center wins, a multi billion dollar arrangement with Brookfield Asset Management, and a new US$600m credit facility that increased Bloom Energy’s financial flexibility. Against that backdrop, the share...

Edgewise Therapeutics (EWTX) shares were in focus after the company outlined a packed 2026 clinical calendar, detailing timelines for pivotal trials, planned regulatory filings, and key readouts across its muscle and cardiovascular programs. See our latest analysis for Edgewise Therapeutics. The recent clinical roadmap has coincided with strong momentum in the share price, with a 59.73% 90 day share price return but a 9.34% decline in 1 year total shareholder return. The 3 year total...

American Airlines recently partnered with award-winning Pecan Lodge to offer Texas-style barbecue on select Dallas–Fort Worth to New York routes and received multiple analyst upgrades citing fleet renewal and premium product focus. Together, these moves highlight how American is leaning on differentiated customer experience and analysts’ improving views of its business direction to influence investor sentiment. We'll now explore how American’s premium-focused initiatives, such as the Pecan...

If you are wondering whether CareDx at around US$20.19 is starting to look interesting again, you are not alone. This article is here to help you think through the value question. The share price has seen a 7.3% gain over the last week, while the 30 day return sits at a 1.8% decline and the 1 year return is a 8.4% decline. This is against a 42.3% gain over 3 years and a 78.4% decline over 5 years. Recent news coverage of CareDx has focused on how investors are reassessing the company in...

Tradeweb Markets Inc. reported past record total trading volume of $63.0 trillion for December 2025 and $185.3 trillion for the fourth quarter, with average daily volume for both periods rising very large year over year and preliminary fee metrics highlighting the scale of its electronic trading activity. The combination of surging volumes and disclosed preliminary variable and fixed fees offers a clearer view of how Tradeweb is converting higher activity into revenue. Next, we will examine...

Biogen recently received European Commission marketing authorization for a high-dose SPINRAZA regimen to treat 5q spinal muscular atrophy, covering rapid-loading 50 mg doses followed by 28 mg maintenance injections every four months. This decision, grounded in the DEVOTE Phase 2/3 trial showing statistically significant motor function gains with a safety profile consistent with nusinersen, meaningfully broadens treatment options for the vast majority of SMA patients in Europe. We’ll now...

Alumis (ALMS) is back in focus after reporting positive Phase 3 ONWARD1 and ONWARD2 results for its TYK2 inhibitor envudeucitinib in plaque psoriasis, followed by a completed US$300.05 million follow-on equity offering. See our latest analysis for Alumis. The upbeat Phase 3 data and follow on equity offering have coincided with strong near term momentum, with a 30 day share price return of 92.43% and a year to date share price return of 146.90%, while the 1 year total shareholder return of...

If you are wondering whether Coeur Mining's recent share price puts it at an attractive entry point, the next sections will walk through what the current valuation might be telling you. The stock last closed at US$20.96, with reported returns of 6.8% over 7 days, 21.5% over 30 days, 19.4% year to date and 230.1% over the past year. This naturally raises questions about both opportunity and risk at today’s price. Investors have been reacting to company specific developments and broader moves...

UBS’ decision to downgrade Perimeter Solutions (PRM) from Buy to Neutral, while the company funds its Medical Manufacturing Technologies acquisition through a $550 million note offering, has put the stock’s risk and return trade off in sharper focus. See our latest analysis for Perimeter Solutions. At a share price of $28.08, Perimeter Solutions has seen a 24.58% 3 month share price return and a 116.33% 1 year total shareholder return. This suggests recent momentum remains positive even as...